A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer

Biogen logo

Biogen

Status and phase

Completed
Phase 1

Conditions

Non-Small Cell Lung Cancer

Treatments

Drug: BIIB022 With Paclitaxel and Carboplatin

Study type

Interventional

Funder types

Industry

Identifiers

NCT00970580
212-LC-101

Details and patient eligibility

About

The purpose of this study is to determine whether BIIB022, Paclitaxel and Carboplatin are effective in the treatment of Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer.

Enrollment

18 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age >/= 18 years old
  • Treatment-naive Stage IIIB/IV Non-Small Cell Lung Cancer
  • ECOG Performance Status 0 or 1

Exclusion criteria

  • History of another primary cancer within 3 years
  • Any prior or concurrent investigational or standard therapy for treatment of NSCLC
  • Prior anti-IGF-1R therapy
  • Unstable diabetes

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

18 participants in 1 patient group

BIIB022 in Combination with Paclitaxel and Carboplatin
Experimental group
Description:
BIIB022 in Combination with Paclitaxel and Carboplatin
Treatment:
Drug: BIIB022 With Paclitaxel and Carboplatin

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems